An insightful workshop titled “Accelerated Pathway from Antibody to ADC,” presented by Dr. Nareshkumar Jain, CEO of NJ Bio, took place at Dr. Reddy’s Institute of Life Sciences (DRILS) on 7th January 2025.This event was held in partnership with Cohance Life Sciences, Suven Pharmaceuticals, and NJ Bio. The session offered an in-depth exploration of antibody-drug conjugates (ADCs), focusing on their design, mechanisms, and significant impact on targeted cancer treatments. Dr. Jain’s ability to simplify intricate ideas and his commitment to furthering medical science contributed to an enlightening experience, serving as a catalyst for innovation in the healthcare sector.
